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Peritoneal transport in CAPD patients with permanent loss of ultrafil-
tration capacity. During a 10 year period, 14 out of 227 patients (6.2%)
undergoing continuous ambulatory peritoneal dialysis (CAPD) devel-
oped permanent loss of ultrafiltration capacity (UFC). The risk of UFC
loss increased from 2.6% after one year to 30.9% after six years of
treatment. A six hour, single dwell study with glucose 3.86% dialysis
fluid was carried out in nine of the UFC loss patients and in 18 CAPD
patients with normal UFC. Intraperitoneal dialysate volumes were
calculated using t3hLtagged albumin (RISA) as volume marker with a
correction applied for its elimination from the peritoneal cavity. The
RISA elimination coefficient (Ks), which can serve as an estimation of
the upper limit of the lymphatic flow, was also calculated. Diffusive
mass transport coefficients (KBD) for investigated solutes (glucose,
creatinine, urea, potassium, total protein, albumin and 132-microglob-
ulin) were calculated during a period of dialysate isovolemia. Two
patterns of UFC loss were observed: (a) seven patients had high KBD
values for small solutes resulting in rapid uptake of glucose, whereas
KBD values for proteins were normal; (b) two patients had normal KBD
values but a threefold increase both in the fluid reabsorption rate and
K. We conclude that loss of the osmotic driving force (due to
increased diffusive mass transport for small solutes) and increased fluid
reabsorption (possibly due to increased lymphatic reabsorption) are the
two major causes of permanent loss of UFC in CAPD patients.
Failure to remove excess fluid due to the apparent loss pf
peritoneal ultrafiltration capacity (UFC) over a four to six hour
dialysis exchange is a common complication in patients under-
going continuous ambulatory peritoneal dialysis (CAPD). In
some cases this may be due to catheter malfunction resulting in
impaired drainage and therefore an increased residual volume
[1, 2]. More commonly a fall in UFC is often noted immediately
before [3] and during [4—8] peritonitis, but this alteration is
reversible and UFC usually returns to normal within one month
[3—5]. Finally, permanent loss of UFC may occur during long-
term treatment with CAPD. The incidence of this complication
has earlier been reported to vary between 3% and 100% in
different reports [9—15], whereas recent studies of large patient
populations indicate that 1.3% to 6.0% of CAPD patients have
to be withdrawn from the treatment because of UFC loss
[16—19]. We have previously reported that 5 out of 124 CAPD
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patients had to cease peritoneal dialysis because of loss of UFC
[20].
The pathophysiological mechanism(s) behind permanent loss
of UFC have not yet been established. Some authors have
emphasized the role of increased peritoneal solute transport
[11, 21] with a 'hyperpermeable peritoneum" due to reversible
mesothelial alterations [21], whereas others have suggested the
possible impact of increased lymphatic absorption [22—24]. A
third possibility is that formation of adhesions and sclerosis
such as during the development of sclerosing peritonitis could
result in a "hypopermeable peritoneum" and lead to loss of
UFC [21]. However, pentoneal transport kinetics have not
previously been systematically evaluated in patients with per-
manent loss of UFC.
The aim of the present study was to evaluate peritoneal fluid
and solute transport characteristics during a peritonitis free
interval in CAPD patients with permanent loss of UFC com-
pared to patients without UFC loss.
Methods
Patients
During the period of 1979 to 1988, 14 out of 227 patients who
had completed CAPD training at our center developed perma-
nent clinical loss of UFC defined as: edema and inability to
reach "dry weight" despite three or more hypertonic ex-
changes (3.86%) per day and a restricted fluid intake with
duration of symptoms of overhydration exceeding one month,
and finally, no established cause of UFC loss such as peritoni-
tis, dialysate leakage or catheter malfunction.
Nine of the 14 CAPD patients with loss of UFC were included
in the present study and were investigated with a six-hour dwell
study. There were four women and five men. Their ages were a
mean of 59 13 (± SD) years (range 36 to 71 years). The cause
of chronic renal failure was chronic glomerulonephritis, poly-
cystic kidney disease, eclampsia, secondary amyloidosis, bilat-
eral renal artery stenosis, and interstitial nephritis in one case
each and diabetic nephropathy in three patients (one patient had
diabetes mellitus type 1 and two patients had diabetes mellitus
type 2). All patients with loss of UFC were anuric or had only
minimal residual renal function. Their estimated overhydration
determined from the difference between their body weight at
the time of the dwell study and their clinically estimated "dry
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Table 1. Patient characteristics in nine CAPD patients with permanent toss of ultrafiItration capacity and 18 CAPD patients with normal UFC
Patient no.
T ATCAPD UCL R
N/N
Body wt
kg
%L
body wt
%
Body wt0
kg
BP
mm Hg
V
ml/24 hr
PIT
N
N-PIT
monthsmonths
UFC loss 1 25 1 5/5 71.3 106 67 170/90 117 2 3
2 19 4 4/5 67.5 113 56.5 175/80 <100 2 8
3
4
61 4
30 6
3/4
3/4
75.4
79.1
108
114
75
76.5
160/85
170/95
0
<100
4
1
5
4
5 12 8 4/4 71.8 126 60 170/80 <100 1 8
6 37 5 4/4 71.5 97 69 230/100 0 2 20
7 72 8 4/5 63.0 102 61 170/100 0 3 4
8 1 1 3/4 75.8 105 73 110/70 <100 0 —
9 58 5 3/4 59.7 103 53.5 140/70 0 7 4
Mean SD 35 24 4.7 2.5 3.7 0,fib/
4.3±0.5
70.6 6.3 108 9 65,7 8.7° 166 32/
86±12
<100 2.4 2.1 7.0 56d
Controls Mean SD 17 17 — 1.3 0.9/ 62.3 12.6 95 16 — 138 38/ 107 1.6 3.5 4.7 4.7"(N = 18) 4.1 0.4 77 12
Abbreviations are: TCAPD, time on CAPD; TUFL, duration of UFC loss; R. ratio of number of hypertonic/total number of exchanges in 24 hours;
Body wt, body weight; % I body wt, % ideal body weight; Body wt0, body weight one month before the start of UFC loss symptoms; BP, blood
pressure; V, urine volume; PIT, number of previous peritonitis episodes; N-PIT, interval between last episode of peritonitis and study.
Significant difference IJFC loss vs. controls are marked: a p < 0.05, and b p < 0.001. Significant difference body wt0 vs. body weight at the
time of the study (body wt), P < 0.01. " For patients with peritonitis episodes.
weight" was on average about 4 kg (range 0.5 to 13.5 kg). This
value corresponded well with the difference between their body
weight at the dwell study and one month prior to the first signs
of fluid overload, 4.8 4.0 kg. The interval between the study
and the last episode of peritonitis was from 3 to 20 months
(mean 7.0 months). Patient characteristics are given in Table 1.
Additional studies were carried out in three patients investi-
gated before loss of UFC (patients no. 7 and 9) or re-investi-
gated later (patients no. 3 and 9; see Results).
Control patients
The control group included 18 CAPD patients (8 men and 10
women), mean age 58 12 years (range 33 to 73 years), with no
UFC problems. They had been free from peritonitis for at least
one month before the study. These dwell studies were made as
part of a long-term follow-up of CAPD patients [25]. Clinical
characteristics of the control patients are summarized in Table
1.
Dialysis technique
CAPD was performed according to standard methods as
previously described [20] with dialysis fluid containing glucose
as osmotic agent and lactate as buffer. In addition, two patients
(patients no. 7 and no. 9) had used one daily exchange of 2 liters
of a 1% amino acid solution (Baxter 151 solution, Baxter-
Travenol, Halden, Norway) [26] for 19 and 26 months, respec-
tively.
Study protocol
Each patient participated in a six-hour dwell study with 2
liters of glucose 3.86% dialysis fluid (Dianeal, Baxter-Travenol)
supplied in plastic bags (Viaflex, Baxter-Travenol). The elec-
trolyte and buffer concentrations were: sodium 132, calcium
1.75, magnesium 0.75, chloride 102, and lactate 35, all in
mmollliter. The dialysis fluid contained 210 2 mmol/liter
glucose, and the total osmolality was 478 3 mOsmollkg.
The patients were studied in the morning after an overnight
oral fast. Overnight dialysate (Dianeal glucose 1.36% in all
except three cases) was drained at 7.15 a.m. Fresh dialysis fluid
(Dianeal glucose 3.86%) was prewarmed to 37°C and prepared
with a priming dose of 0.2 g of human serum albumin to
minimize the adhesion of the tagged albumin to the surface of
the plastic material. Radioisotopically labelled albumin (185 kBq
'311-human serum albumin (RISA), Institutt for Energiteknikk,
Kjeller, Norway) was added and the fluid was then infused
through an infusion set (CAPD Solution Transfer-set, Travenol
Laboratories). Fresh dialysis fluid samples were taken from the
bag halfway through infusion. Dialysate samples (15 ml) were
taken through a three-way stop-cock (Viggo, Connecta, Hels-
ingborg, Sweden) and an indwelling permanent Tenckhoff cath-
eter at 3, 15, 30, 60, 90, 120, 180, 240 and 360 minutes after the
complete infusion of the dialysis fluid. Prior to each sampling,
10 ml of the dialysate was flushed back and forth five times
through the stop-cock. Blood samples were drawn at 0, 180 and
360 minutes (0, 30, 60, 180, 240, and 360 mm for determination
of glucose). After 360 minutes, the dialysate was drained and
the volume recorded. The peritoneal cavity was then rinsed for
five minutes with 1 liter of fresh 1.36% glucose dialysis fluid
(without RISA) to provide data for calculation of the residual
volume at 360 minutes.
The patients were instructed to sit up or to move about in bed
before each sampling of dialysate; otherwise they were recum-
bent throughout the six hour investigation. Informed consent
was obtained from each patient, and the study was approved by
the Ethical Committee of the Karolinska Institute at Huddinge
University Hospital.
Analytical methods
Blood and dialysate samples were analyzed for RISA activity
on an Intertechnique CG Gamma Counter (Intertechnique,
Plaisir, France). Glucose, urea, creatinine, and total protein
were measured with an IL 919 system, sodium and potassium
with an IL 743 flame photometer (Instrumentation Laboratory,
Milan, Italy), and osmotality on a Wescor vapor pressure
osmometer (Wescor Inc., Logan, Utah, USA). Albumin was
analyzed (in 7 UFC loss patients and in 6 of the control patients)
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using an immunoturbidometric method and /32-microglobulin
was analyzed (in 6 UFC loss patients and in 5 of the control
patients) by the Phadebas RIA method (Pharmacia, Uppsala,
Sweden).
Calculations VD(t):
Intraperitoneal dialysate volumes (YD) were estimated from
the dilution of RISA with a correction applied for the elimina-
tion of RISA from the peritoneal cavity, as described previously
[25, 27, 28].
Briefly, to solve the problem of peritoneal volume determi-
nation, we assume that the disappearance of albumin from the
pentoneal cavity can be described by the first order kinetics.
d(VD(t) CR(t))Idt = —KE CR(t)
where KE is the albumin elimination coefficient, VD(t) and CR(t)
are the peritoneal volume and volume marker concentration,
respectively. Solution of equation (I) gives
V(t) CR(t) =
—KEJCR(r)dr + VD(O) CR(O) (2)
0
The apparent peritoneal volume, VA(t), can be calculated from
the equation
VA(t) CR(t) = V(0) CR(0)
where CR(t) is the concentration of RISA, and VD(O) CR(O) is
the amount of labelled albumin at the beginning of the dialysis.
Using (3) in equation (2), the formula for calculation of the
albumin elimination coefficient is obtained:
VA(t) — V(t)KE = __________
VA(t)f7
At the termination of dialysis (the termination time t =T), the
dialysis fluid was collected from the peritoneal cavity. The sum
of the removed volume of dialysis fluid, VOUT, plus the residual
volume, VREs, represents the peritoneal space volume at the
termination of dialysis, VD(T);
V(T) = VOUT + VRES
The residual volume, VRES, was determined according to the
tracer dilution principle using the 1 liter 1.36% rinsing dialysis
fluid after termination of dialysis (vide supra). Knowing the
concentration of labelled albumin at the termination of dialysis,
the volume of the rinsing fluid and the concentration of labelled
albumin in the rinsing fluid removed, VRES could then be
calculated.
Using equations (4) and (5) one gets
VA(T) — (VOUT + VRES)
T
0
where VA(T) is the apparent peritoneal volume at the termina-
tion of dialysis.
Finally, having calculated KE from equation (6), equation (4)
is rearranged for calculation of the peritoneal space volume,
g dr
VD(t) = VA(t) — KE VA(t) I (7)j VA(T)
0
To avoid the problem involved in calculation of solute transport
due to convection, the diffusive mass transport area coefficients
(KBD) were calculated during a period of dialysate isovolemia
(1) [27, 28]
dCD(t)
d(t)
= KBD(CB(t) — CD(t)) (8)
and assuming that that C is constant during the evaluation
time,
V CB — CD(tI)
KBD= ln ) (9)
t2 — t1 CB — CD(12
where t1 and t2 are times of beginning and termination of
dialysate isovolemia, respectively.
(3) Dialysate isovolemia (defined as volume changes less than
during one hour) occurred between 60 and 120 minutes in
three of the nine patients with UFC loss and between 120 and
180 minutes in the six other patients. In the control patients,
isovolemia occurred between 120 and 180 minutes (N =9) or
between 180 and 240 minutes (N = 9). The recorded volume
change during isovolemia varied between 0.1% and 3.9% (mean
(4) 1.1%) in the whole group of investigated patients (N =27).
Statistical methods
The risk of loss of UFC was calculated using the life table
analysis method according to Peto et al [29]. Student's t-test for
paired and unpaired data and calculation of the correlation
coefficient were used to evaluate the results. When the three
patient groups were compared analysis of variance (ANOVA)
was used for single and repeated measurements. When
ANOVA single measurements showed significant differences
Scheffe's F-test was used to further analyze differences be-
(5) tween the groups. Data are expressed as mean SD, unless
otherwise noted. Statistical significance was accepted if P <
0.05.
Results
Permanent loss of UFC occurred in 6.2% among a total of 227
CAPD patients during a ten year period and the risk of UFC
loss increased with time on CAPD (Fig. 1). Thus, the cumula-
tive risk of developing permanent loss of UFC was 2.6% after
one year, 9.5% after three years and 30.9% after six years of
treatment with CAPD.
(6) The loss of UFC was found to be permanent in the nine
patients included in the present study. Thus, none of the
patients recovered sufficient peritoneal UFC to continue their
treatment with CAPD. Six patients were transferred to treat-
ment with cyclic continuous peritoneal dialysis (CCPD) (pa-
KE=
VA(T
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tients no. 3 to 6, 8 and 9), two patients were transferred to
hemodialysis (patients no. 2 and 7) and one patient (no. 1) was
transplanted. Seven of the patients died within 3 to 31 months
after the study whereas two patients (no. 3 and 9) were alive on
CCPD, 41 and 10 months, respectively, after the study. None of
the patients with loss of UFC developed scierosing peritonitis.
The UFC loss patients differed in several respects from the
control patients with normal UFC (Table 1). The duration of
previous treatment with CAPD was longer and their percentage
ideal body weight (based upon medium framed individuals,
Metropolitan Life Insurance Table [30]) was higher than in the
control patients. The mean daily number of hypertonic ex-
changes with glucose 3.86% dialysis fluid was 3.7 versus 1.3 in
the control patients (Table 1). However, neither blood pressure,
residual renal function nor the mean number of previous
episodes of peritonitis differed between the UFC loss patients
and the control patients (Table 1). The incidence of peritonitis
was one episode per 14.3 months in the patients with loss of
UFC and one episode per 10.6 months in the control patients.
The blood glucose, hemoglobin and serum levels of urea,
albumin and total protein during the dwell study did not differ
between the patients with loss of UFC and the control patients.
The serum creatinine concentration was slightly lower in the
patients with UFC loss, 813 267 j.tmol/liter compared with
1052 245 mol/liter in the control patients (P < 0.05, t-test).
The patients with loss of UFC (N = 9) showed a markedly
decreased effluent volume 1858 334 ml (N = 9) compared to
2626 248 ml in the control patients (P <0.001, f-test). The
calculated residual intraperitoneal volume did not differ be-
tween the UFC loss patients and the control patients. Patients
with loss of UFC exhibited a shift of the volume over time curve
to the left compared with the control patients (Fig. 2). Thus,
maximum intraperitoneal volume was reached at 110 34 mm
in the UFC loss patients compared to 167 62 mm (P < 0.05,
t-test) in the control patients. The maximum dialysate volume
was lower, 2639 178 ml compared to 3148 221 ml (P <
0.001, f-test) in the control patients. Finally, the reabsorption of
fluid during the last two hours of the study was markedly
enhanced, 2.7 1.5 mI/mm in the patients with loss of UFC (N
= 9) compared to 1.3 0.7 mI/mm in the control patients (P <
0.01, f-test). KE correlated with the fluid reabsorption rate
between 240 and 360 mm (r = 0.702; P < 0.001) in the combined
material of all investigated patients (N = 27).
Two different patterns of loss of UFC were observed (Fig. 2,
Table 2). Two patients (no. 1 and 2) with the highest fluid
reabsorption rates (4.6 mI/mm between 240 and 360 mm in each
case), also exhibited a marked increase in their elimination of
RISA from the peritoneal cavity (KE values were 4.9 and 5.0
mi/mm, respectively, compared to 1.9 0.5 ml in the control
patients, Table 2). These two patients also had the lowest
dialysate effluent volume (Table 2) and the volume over time
pattern (Fig. 2), and solute transport characteristics (Table 3)
differed from the other seven patients with loss of UFC (pa-
tients no. 3 to 9). The KBD values in these two patients did not
differ from the values in the control patients (Table 3). Hereaf-
ter, this group (patients no. 1 and 2) will be referred to as "High
LAR" (high lymphatic absorption rate) since increased elimi-
nation of RISA and fluid from the peritoneal cavity in these two
patients was conceivably due to increased lymphatic absorp-
tion. Although it may be questionable to analyze only two
patients as one group, the differences between patients 1 and 2
from the other seven patients were unequivocal and can not be
neglected because statistical analyses showed highly significant
differences between the two subgroups of UFC loss patients
(Table 2 and 3).
In the other group of UFC loss patients (patients no. 3 to 9,
hereafter referred to as "High KBD") KBD values for creati-
nine, urea and glucose were significantly increased whereas KE
was normal (Tables 2 and 3). In the High KBD group changes in
fluid transport (Table 2, Fig, 2) were associated with marked
alterations in solute transport (Table 3). The dialysate glucose
concentration decreased faster (Fig. 3) and the total glucose
uptake was markedly increased in the High KBD group; 50% of
the initial amount of glucose (at 3 mm) was absorbed at 100
100•
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Fig. 1. Cumulative risk of developing permanent loss of UFC vs. time
in 227 CAPD patients who started on CAPD 1978—1988.
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Fig. 2. Intraperitoneal dialysate volume (mean SD) vs. time during a
six-hour dwell study in nine CAPD patients with loss of UFC associated
with high lymphatic absorption rate (High LAR, N = 2, A) and
increased diffusive mass transport (High KBD, N = 7, ii), respectively,
and in CAPD patients with normal UFC (Controls, N = 18, E).
ANOVA (repeated measurements) showed significant differences be-
tween the High LAR group vs. Controls (P < 0.001) and between the
High KBD group vs. Controls (P < 0.001).
0 60 120 180 240 300
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Table 2. Ultrafiltration characteristics in nine CAPD patients with permanent loss of UFC and 18 CAPD patients with normal UFC (Controls)
during a six hour exchange with glucose 3.86% dialysis fluid
Type of UFC loss Patient no.
OUT VRES VD max Tmax
mm
VD/1t
mi/mm
(VA — V0)
100/V0 %
KE
mi/mmml
High LAR 1
2
Mean SD
1459
1275
1367 130
126
197
162 50
2586
2537
2562 35
120
90
105 21
4.6
4.64.6 00b
125
136
131 8b,d
4.9
5.0
4•9
High K0 3
4
5
6
7
8
9
Mean SD
1815
1795
2190
1790
1970
2260
2170
1999 206"
247
497
177
392
130
53
137
233 158
2589
2697
2777
2577
2359
3002
2631
2662 198"
120
120
180
90
120
60
90
111 38
3.0
0.5
3.0
1.7
1.2
3.8
2.2
2.2 1.2
40
47
31
38
28
45
38
38 7"
2.2
2.6
1.9
2.1
1.5
2.8
2.2
2.2 0.4
Controls (N = 18) Mean SD 2626 248 319 140 3148 221 167 62 1.3 0.7 21 5 1.9 0.5
Abbreviations are: High LAR, high lymphatic absorption rate; High KBD, high diffusive mass transport coefficients (KBD); VOUT, recorded
dialysate effluent volume; RES, residual peritoneal dialysate volume at 360 mm; VD max' maximum intraperitoneal dialysate volume; Tvmax, time
to reach VD max; —V0/t, rate of net fluid reabsorption between 240 mm and 360 mm; (VA — V0) 100/VD, difference (error) at 360 mm between
true dialysate volume (VD) and apparent dialysate volume estimated from the dilution of RISA without correction for tracer removal (VA)
expressed as percentage of D; KE, elimination rate of RISA from the peritoneal cavity.
Significant differences for High LAR and High K0, respectively, vs. controls are marked: a P < 0.01, and b P < 0.001. Significant differences
for High LAR vs. High KBD are marked: C p < 0.01, and d P < 0.001.
3 28.7
4 20.7
5 17.4
6 19.1
7 21.5
8 18.5
9 16.5
Mean SD 20.4 41b
41.0
27.4
45.6
54.2
30.0
60.2
43.1 130b
Controls (N = 18) Mean so 10.7 2.7 10.6 5.7 29.5 11.9 12.8 5.5 0.086 0.038 0.053 0.023" 1.48 l.06
Abbreviations are in Table 2.
Significant differences High LAR and High KBD, respectively, vs. controls are marked: a P < 0.05, and b p < 0.001.
Significant differences High LAR vs. High KBD are marked: C P < 0.001
dN 6N 5
29 mm in the High KBD group compared with 203 56 mm in
the control patients (P < 0.001, t-test). The dialysate/plasma
creatinine concentration ratio was markedly increased in the
High KBD group (Fig. 4).
The dialysate sodium level was higher in the High KBD group
(Fig. 5). KBD values for sodium were not taken into account in
this study because, when using equation (9) during dialysate
isovolemia, intraperitoneal sodium concentrations were close
to plasma concentrations, resulting in rather large errors in KBD
estimations for this solute. The peritoneal sodium balance was
strongly correlated to the calculated net ultrafiltration at 360
minutes (r = —0.974; P <0.001, N = 27, Fig. 6). In spite of a
higher dialysate sodium concentration in patients with loss of
UFC, the mean peritoneal sodium balance over the six hour
dwell tended to be positive in UFC loss patients (+21.1 46.9
mmol after 6 hours, N = 9), showing that the patients with loss
of UFC were retaining both water and sodium. In contrast, a
negative sodium balance was found in the control patients
(—56.9 23.1 mmol after 6 hours, N = 18) (significant differ-
ence compared with the patients with UFC loss; P < 0.001).
The plasma and dialysate osmolality did not differ between
the three groups (Fig. 7).
The peritoneal transport rate of proteins in UFC loss patients
did not differ from that of the control patients. As shown in
Table 3, KBD values for total protein as well as for albumin and
132-microglobulin did not differ between the High KED group
and the control patients. Furthermore, the amount of dialysate
total protein during and at the end of the dwell study did not
differ between the patients with UFC loss and control patients
(2.78 1.12 g and 2.62 0.72 g, respectively, at 360 mm, NS,
High LAR 1
Table 3. Solute
and in
transport characteristics (diffusive mass transport area coefficients (K50)) in nine CAPD patients with permanent loss of UFC
18 CAPD patients with normal UFC (Controls) during a six hour exchange with glucose 3.86% dialysis fluid
UF loss
KBD mi/mm
Type of Patient no. Glucose Creatinine Urea Potassium Total protein Albumin 132-microglobulin
High K50
13.6
2 17.3
Mean SD 15.4 2.6
10.7
17.6
14.2 49C
12.1
24.2
18.1 8.6
0.036
0.082
0.059 0.032
26.3
24.5
25.4 1.3
123.9
33.7
25.3
30.9
82.9
59.3 42.8a
18.3 0.163
14.8 0.105
17.2 0.110
19.8 0.112
11.8 —
20.2 0.035
8.8 0.064
15.8 4.3 0.098 0.044
0.014
0.042
0.204
0.115
0.078
0.044
0.064
0.080 0.063
1.85
0.97
1.82
0.95
1.95
1.14
1.45 0.47
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Fig. 4. Dialysatelplasma creatinine concentration ratio (DIP) (mean
SD) vs. time during a six-hour dwell study with 3.86% glucose solution.
Symbols as in Fig. 2, (High KBD, N = 6, no data available for patient
no. 3). ANOVA (repeated measurements) showed significant difference
between the High KBD group vs. High LAR (P < 0.001) and between
the High KBD group vs. Controls (P < 0.001).
f-test). However, because of the lower dialysate volume in
which the protein was distributed, the dialysate protein concen-
tration was higher during the whole dwell in the patients with
UFC loss (P < 0.05 to P < 0.01, f-test) with a value at 360
minutes of 1.33 0.47 glliterin the patients with loss of UFC (N
= 9) compared to 0.89 0.24 glliter in the control patients (P <
0.01, f-test).
Consecutive dwell studies were carried out in three of the
patients. Two patients (no. 7 and 9) were investigated prior to
the first signs of loss of UFC (after 31 and 2 months on CAPD,
respectively). At this time they had normal UFC and glucose
absorption (Fig. 8) and their KBD and KE values were normal
(data not presented here). Patient no. 9 was studied shortly after
the start of UFC loss (second dwell, after 58 months on CAPD)
0 60 120 180 240 300 360
Time,minutes
Fig. 5. Dialysate sodium concentration (mean SD) vs. time during a
six-hour dwell study with 3.86% glucose solution. Symbols as in Fig, 2.
ANOVA (repeated measurements) showed significant differences be-
tween the High LAR group vs. Controls (P < 0.001) and between the
High KBD group vs. Controls (P < 0.001).
and was studied again three months later (third dwell, after 61
months on CAPD) and did not show any improvement.
Patient no. 3 was investigated after 61 months on CAPD
(Table 1). He was then successfully managed on CCPD despite
significant UFC loss, and was investigated again after another
35 months (total of 96 months on PD). The second dwell study
still showed elevated KBD values (data not presented here) and
a marked decrease in UFC compared with the control patients
(Fig. 9).
Discussion
In this study, the dialysate volume over time profile, residual
volume, mass transport from blood to dialysate (urea, creati-
nine, sodium, potassium, total protein, 32-microglobulin and
albumin) as well as from dialysate to blood (glucose) were
evaluated in a group of patients with permanent loss of UFC. In
addition, assuming that albumin (RISA) removal occurs mainly
via the lymphatics, the maximum possible lymphatic absorption
rate of fluid and solutes from the peritoneal cavity was esti-
mated as the RISA elimination coefficient (KE).
Although the peritoneal membrane and surrounding tissues is
a complex system which is much more complicated than
assumed in this model (that is, the peritoneal membrane is
probably not homoporous [31]), a simple phenomenological
approach is considered to be the most feasible method for the
evaluation of clinical data on peritoneal transport [22, 24, 27,
28, 32, 33].
Theoretically, impaired UFC could be caused by 1) ob-
structed outflow [1, 2], 2) decreased net transcapillary ultrafil-
tration rate due to increased solute transport or surface area and
therefore increased absorption of glucose and loss of the
osmotic driving force [11, 21], 3) a "hypopermeable peritone-
urn" with decreased water permeability or decreased surface
area [21], 4) increased lymphatic flow [22—24], or a combination
of these factors. The results in this study indicate that increased
peritoneal transport rate for small solutes, resulting in loss of
the osmotic driving force, is the major cause of permanent loss
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Fig. 3. Dialysate glucose concentration (mean SD) vs. time during a
six-hour dwell study with 3.86% glucose solution. Symbols as in Fig. 2.
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of UFC in CAPD patients. In addition, increased lymphatic
absorption may explain the apparent loss of UFC in some
patients. In the following, the above-mentioned possible causes
of UFC loss are discussed in detail.
Obstructed outflow
The residual volume was not increased among the patients with
UFC loss. Thus, mechanical obstruction of dialysate outflow was
ruled out as a cause of UFC loss in the investigated patients.
Increased solute transport
The present findings that increased KBD values for small
solutes is the prevailing feature in patients with loss of UFC
confirms previous clinical observations of increased net trans-
port of glucose and other small solutes in CAPD patients with
impaired UFC not related to peritonitis [3, 11, 21, 33—39].
Furthermore, a negative correlation between ultrafiltration and
glucose absorption was observed in the International Coopera-
tive Study among 317 CAPD in whom effluent volume from a
four-hour hypertonic dwell was used as a measure of UFC [401.
Altogether these observations demonstrate the close interrela-
tionship between fluid and glucose transport and underline the
clinical importance of simultaneous evaluation of fluid and
solute transport parameters in CAPD patients with impaired
UFC. This evaluation can be carried out by the single dwell
study design or by using simplified protocols such as the
peritoneal equilibration test [41, 42].
In spite of the more rapid decrease of dialysate glucose
concentration in the High KBD group (Fig. 3), the dialysate and
plasma osmolality did not differ between the UFC loss patients
and control patients (Fig. 7). This can be explained by the faster
diffusion of small solutes other than glucose from blood to
dialysate in the High KBD group (Table 3). The osmotic
pressure difference over the peritoneal membrane is not directly
related to the osmolality, but to the sum of products of the
molar concentrations of solutes and their reflection coefficients
[43].
The increase of KBD values for small solutes in our patients
was similar to the reported changes in solute transport during
peritonitis [4, 5, 7, 8]. However, peritonitis is associated with
increased transport rates of proteins [4—8, 44]. In contrast, KBD
values for total protein, albumin and 2-microglobulin were not
increased in our patients. Similar results were obtained in a
previous study of patients with poor UFC without peritonitis
[33]. Therefore the mechanisms behind increased KBD values
for small solutes in patients with permanent loss of UFC might
be different than during peritonitis.
The increase of small solute transport but not of protein
transport in our patients with permanent loss of UFC is in
agreement with the two pore model which suggests hetero-
porous transport of small solutes and macromolecules [31]. It
should be noted that although the present study was carried out
during a period of dialysate isovolemia, the parameter KBD
does not exclude the possibility that also convection is of
importance for macromolecular transport through the perito-
neal barrier [31, 45]. However, data supporting a major role of
restricted diffusion of macromolecules in peritoneal transport
have also been presented [46].
The finding that there was no correlation between permanent
loss of UFC and previous number or incidence of peritonitis in
our patients is in agreement with several previous studies [10,
33, 34, 40].
Decreased solute transport
It has been reported that UFC loss could also be caused by a
"hypopermeable peritoneum" in the development of sclerosing
peritonitis [21]. In contrast, recent detailed studies in four
patients developing scierosing peritonitis, showed an increasing
mass transfer area coefficient (MTC, equivalent to KBD in this
study) in three of the patients [47], suggesting that the observed
loss of UFC in these patients was an early sign that preceded
the development of more overt signs of sclerosing peritonitis.
However, none of our patients with UFC loss have developed
clinical signs of sclerosing peritonitis.
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Fig. 8. Intraperitoneal dialysate volume and dialysate glucose concentration, respectively, vs. time during a six-hour dwell study with 3.86%
glucose solution in two CAPD patients. Patient no. 7 developed clinical signs of UFC loss after 64 months on CAPD and was investigated after
31 and 72 months on CAPD. Patient no. 9 developed clinical signs of UFC loss after 53 uionths on CAPD and was investigated after 2, 58 and 61
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Increased lymphatic flow
Several recent studies have emphasized the importance of
lymphatic flow in peritoneal dialysis [37, 48, 49] and it has been
suggested that loss of UFC may occur in patients with increased
lymphatic absorption [22—241. However, increased absorption
of albumin or other macromolecular tracers suggesting in-
creased lymphatic absorption in patients with UFC loss has
previously been reported only in one patient [23].
KE is an estimate of the rate of labelled albumin transport into
the lymphatics (and adjacent tissue spaces), and the finding that
KE (but not KBD) was markedly increased in two of our patients
may therefore suggest that increased lymphatic absorption was
the cause of UFC loss in these two patients. Furthermore, these
two patients had markedly increased fluid reabsorption rates
(Table 2, Fig. 2), suggesting increased fluid absorption by the
lymphatics. The magnitude of the lymphatic absorption rate has
been debated [50—53] since attempts to correlate the disappear-
ance of the tracer to its appearance in blood have not been
successful [54, 55]. The divergent findings have led to large
differences in the suggested lymphatic absorption rate from 0.19
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mL/min to 1.9 mI/mm [35, 37, 54—56]. It is, however, unlikely
that an increased tissue binding of the tracer could account for
the more than a twofold increase in KE in patients no. I and 2,
and even then would not explain the severe loss of UFC in these
two patients. Thus, it seems more probable that increased
lymphatic absorption was the cause of these findings. A few
factors are known to increase peritoneal lymphatic flow rate: 1)
raised intraperitoneal hydrostatic pressure, 2) raised diaphrag-
matic movement (hyperventilation), 3) supine posture, and 4)
chemical peritonitis [48]. To our knowledge, none of these
factors differed between the two High LAR patients, the seven
High KBD patients and the 18 control CAPD patients. There-
fore, the cause of increased RISA disappearance remains
unknown in the two High LAR patients. A possible impact of
phosphatidylcholine on lymphatic transport and UFC loss has
also been discussed [57—60].
The estimation of fluid and solute transport parameters is
critically dependent on the accuracy of dialysate volume deter-
minations. If the apparent dialysate volume (MA) is not cor-
rected for the elimination of the tracer from the peritoneal
cavity when calculating the real dialysate volume (VD) a large
systematic error occurs in the calculations of both ultrafiltration
and KBD values. Failure to correct for the influence of tracer
disappearance as estimated by the RISA elimination coefficient
(KE) results in a large overestimation of the calculated volume
at the end of the dwell (Table 2) and a corresponding error in the
calculation of KBD (equation (9), Methods). These consider-
ations underline the necessity to take the disappearance of the
tracer into consideration when evaluating ultrafiltration and
solute transport in individual patients, especially in patients
with loss of UFC.
The problem to correct the calculated KBD values for the
impact of the lymphatic flow on solute transport has not yet
been solved. KBD values calculated during dialysate isovolemia
differ only slightly from the "true" KBD values, an error that
depends on the lymphatic flow (Appendix). However, if the
lymphatic flow is significantly increased, as was thought to be
the case in patients no. I and 2, the error in estimation of KBD
becomes larger. This can perhaps explain the tendency towards
increased KBD values for glucose in patients no. 1 and 2
compared to the control patients (Table 3). Since the true value
of the lymphatic flow is unknown, and we do not know how
much of KE represents lymphatic flow and how much repre-
sents losses into adjacent tissue spaces, this correction can not
be done reliably in individual patients.
Clinical characteristics of UFC loss patients
A correlation between the use of acetate buffered dialysis
fluid and impaired UFC has earlier been reported [12, 38, 40, 61]
and centers using acetate have reported the highest incidence of
UFC problems [10]. Therefore, the exclusive use of lactate as
buffer could explain why the incidence of severe UFC problems
among our CAPD patients is lower than that reported in earlier
studies.
Bacteriological filters have been used in some of the centers
reporting on high incidence of UFC loss [10]. It has been
suggested that bacterial growth in the filters may cause release
of endotoxins into the peritoneal cavity, resulting in stimulation
of synthesis of interleukin-1 which might lead to UF loss and
finally scierosing peritonitis [62]. The use of bacteriological
filters has been limited among our patients [20] and did not differ
between the patients with loss of UFC and the control patients.
Two of the High KBD patients (no. 7 and 9) had used one daily
exchange of a 1% amino acid solution prior to the study for 19
and 26 months, respectively. The dialysate protein loss has
been reported to increase in patients using amino acid solutions
for peritoneal dialysis [63, 64]; however, this phenomenon was
not observed in patients no. 7 and 9. Although the use of amino
acids can not be ruled out as a pathogenetic factor in the
possibly multifactorial genesis of UFC loss, neither of these two
patients showed improvement of UFC after termination of the
use of amino acid solutions.
The risk of developing permanent loss of UFC increased
substantially with time on CAPD (Fig. 1) and the long observa-
tion time in our patients (up to 112 months) could therefore at
least in part explain the higher incidence of this complication
among our patients compared with data from recent studies on
patients treated with lactate buffered solutions [16—18]. The
incidence of UFC loss found in this study (6.2%) is similar to
that found in a eight year study in which 6.0% of the patients
had to be permanently transferred from CAPD because of UFC
loss [19].
In some cases impaired UFC (not related to peritonitis) in
CAPD have been found to be a reversible phenomenon [14, 21].
None of our patients, however, recovered from UFC loss.
Patient no. 3 was treated with CCPD for 35 months and
hemodialysis for two weeks but showed no sign of recovery of
UFC (Fig. 9). Patient no. 7 was treated with hemodialysis for
five weeks and was then restarted on CAPD, but showed no
sign of improvement of UFC and was therefore transferred to
hemodialysis again.
In summary, permanent loss of UFC is a common complica-
tion in patients undergoing long-term treatment with CAPD.
The risk of UFC loss, which increased with time on CAPD and
was 2.6% after one year and 30.9% after six years on CAPD, did
not correlate with the incidence of peritonitis. Increased pen-
toneal transport of small solutes was observed in most patients
with loss of UFC, whereas, unlike the situation during perito-
nitis, the rate of protein transport was not increased. Loss of
UFC was in most cases associated with rapid glucose absorp-
tion and loss of the osmotic driving force, resulting in a low and
short-lived net ultrafiltration. Since a high net transcapillary
ultrafiltration is observed mainly during the two first hours
following instillation of fresh dialysis fluid, patients with loss of
UFC due to increased small solute transport should be trans-
ferred either to CCPD or other short dwell time treatment
modalities or to hemodialysis. Although the rate of fluid absorp-
tion was increased in all nine patients with loss of UFC, this
change was most conspicuous in two patients with normal
diffusive mass transport coefficients. In these two patients thus
representing a different pattern of UFC loss the marked in-
crease of the fluid reabsorption rate was most likely due to
increased lymphatic transport. According to our experience,
patients with this type of more severe UFC loss cannot be
successfully maintained on peritoneal dialysis and thus should
be transferred to treatment with hemodialysis. The results of
this study do not exclude the possibility that the combination of
increased diffusive mass transport and increased lymphatic flow
may occur as a cause of UFC loss. The simultaneous evaluation
of fluid and solute penitoneal transport characteristics as de-
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scribed in this study may serve as a useful diagnostic tool for
the clinical management of patients with loss of UFC.
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Appendix
The error involved in the calculation of KBD during dialysate
isovolemia with lymphatic flow neglected
The influence of lymphatic flow (QL) on peritoneal diffusive
mass transport can be estimated using theory of mass transport
across a homogeneous membrane [64]. Assuming that the
peritoneal barrier can be adequately approximated by a homo-
geneous membrane and that the solute flow via lymphatics from
the peritoneal cavity can be expressed as the product of QL and
solute concentration in peritoneal fluid (CD) then, during iso-
volemia (VD = constant, that is, ultrafiltration flow equals QL)
dC
VDId
K'BD(CB — CD) + [(QL S C) — (QL CD)]
where K'BD is "true" diffusive mass transport coefficient and S
is sieving coefficient and
1 1 SQLC = (1 — f) CB + lCD, f = — — , (3/3 exp/3—1 KED
(2A)
For small solutes, defined as having KBD> 10 ml/min and S
1 and for QL 2 mi/mm, f3 < 0.2. For large solutes (proteins)
defined as having KBD 0.08 mi/mm, S 0.01 [32] and for QL
2 mI/mm, 13 0.25.
It is easy to show using estimated f3 in equation (2A) that for
small as well as for large solutes, f 0.5 and therefore
C = O.S(CB + CD) (3A)
Using equation (3A) in equation (lA) one gets for small solutes
(5 1)
dCD
= (K'BD + 0.5 QL) (CB —CD)
Table 4. Estimation of the error in the calculated value of KBD (error
%) for small and large solutes (sieving coefficient, 5, 1 and 0.01,
respectively) during dialysate isovolemia with lymphatic flow (QL)
neglected, as a function of QL
Error %
Small solutes Large solutes
(S 1) (S 0.01)
QL Total
mI/mm Urea Creatinine Glucose protein Albumin
0.2 0.3 1 1 —1 —2
1.0 2 5 5 —5 —7
2.0 4 10 10 —9 —14
5.0 9 31 30 —20 —28
QL CD\
KOD = K'BD + 0.005 1 + — 1
CD( (
1-•———-—
CB
The average CD/CB ratio for total protein found in this study
was 0.0093 0.0026 during dialysate isovolemia. Using this
value in equation (7A) it can be shown that for proteins KBD
(1A) underestimates K'BD by 0.0042 QL
KED = K'BD — 0.0042 QL (8A)
The error in the calculated value of KBD for small and large
solutes during dialysate isovolemia with QL neglected, as a
function of QL, is shown in Table 4.
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